Cargando…

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study

Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials and Methods: We enrolled patients diagnosed with COVID-19 and comorbidities who were candidates for antiviral drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pontolillo, Michela, Ucciferri, Claudio, Borrelli, Paola, Di Nicola, Marta, Vecchiet, Jacopo, Falasca, Katia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610792/ https://www.ncbi.nlm.nih.gov/pubmed/36297178 http://dx.doi.org/10.3390/pathogens11101121

Ejemplares similares

Parameters associated with diagnosis of COVID‐19 in emergency department
por: Ucciferri, Claudio, et al.
Publicado: (2021)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV
por: Reale, Marcella, et al.
Publicado: (2021)

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
por: Ucciferri, Claudio, et al.
Publicado: (2015)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with telmisartan
por: Ucciferri, Claudio, et al.
Publicado: (2010)

Use of Hematopoietic Growth Factor in the Management of Hematological Side Effects Associated to Antiviral Treatment for Hcv Hepatitis
por: Mancino, Paola, et al.
Publicado: (2010)

Cystatin C and cardiovascular risk in HIV infected patients
por: Falasca, Katia, et al.
Publicado: (2010)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
por: Falasca, Katia, et al.
Publicado: (2015)

Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
por: D’Ardes, Damiano, et al.
Publicado: (2020)

The impact of homocysteine, B(12), and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
por: Falasca, Katia, et al.
Publicado: (2019)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
por: Falasca, Katia, et al.
Publicado: (2017)

Risk Factors Associated with Poor Outcome in Patients with Infective Endocarditis: An Italian Single-Center Experience
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

Early detection of pleuro‐pulmonary tuberculosis by bedside lung ultrasound: A case report and review of literature
por: Cocco, Giulio, et al.
Publicado: (2022)

Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features
por: Cocco, Giulio, et al.
Publicado: (2022)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Air and surface measurements of SARS-CoV-2 inside a bus during normal operation
por: Di Carlo, Piero, et al.
Publicado: (2020)

Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19
por: Renda, Giulia, et al.
Publicado: (2023)

Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation
por: Dufrusine, Beatrice, et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Approach to COVID-19 in older adults and indications for improving the outcomes
por: Tana, Claudio, et al.
Publicado: (2023)

Normal breathing releases SARS-CoV-2 into the air
por: Di Carlo, Piero, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Diaphragmatic myoclonus due to SARS-CoV-2 infection
por: Borroni, Barbara, et al.
Publicado: (2020)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
por: Czarnecka, Kinga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvmbapemf5iq7i484h713gbeud